

August 09, 2024

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Press Release

Attaching herewith a Press Release regarding Caplin Point Laboratories Ltd has been recognized in Forbes Asia's "200 Best Under a Billion" list for the year 2024, a compilation that underscores companies' sustained and robust performance across critical benchmarks. Request you to take the same on record.

Thanking You,

Sincerely Yours
For Caplin Point Laboratories Limited

Venkatram G
General Counsel & Company Secretary
Membership No. A23989
Encl: A/a

Caplin Point listed on Forbes Asia's "200 Best Under a Billion" for 2024

Caplin Point Laboratories Ltd has been recognized yet again in Forbes Asia's 200 Best Under a Billion list for the year 2024, a compilation that underscores companies' sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, 200 enterprises with annual sales under \$1 billion are chosen based on qualitative and quantitative metrics. The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity.

Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said:

"Caplin Point Laboratories Ltd's inclusion in Forbes Asia's '200 Best Under a Billion' list for the seventh time underscores our relentless pursuit of excellence and financial discipline. This recognition, a rare achievement for an Indian pharmaceutical company, reflects our ongoing efforts to strengthening cash flows and ensuring consistent profitability. We are committed to upholding the highest standards in every aspect of our business, ensuring sustained growth and value creation for our stakeholders."

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Subsidiary Caplin Steriles Limited.

Caplin Point listed on **Forbes "Asia's 200 Best Under a Billion" list for 2024**. Company has appeared for the seventh time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

Cautionary Statement:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.

For further information, please contact:

G Venkatram,
General Counsel & Company Secretary
Caplin Point Laboratories

+91 44 2496 8000

investor@caplinpoint.net

Paresh Rohra / Rajiv Pandya
Churchgate Partners

+91 22 6169 5988

caplinpoint@churchgatepartners.com